Exemestane

Exemestane binds to the aromatase enzyme and permanently inactivates it — a suicide inhibitor. This is mechanistically different from Anastrozole and Letrozole which are reversible competitive inhibitors. The permanent inactivation means estrogen suppression continues until new aromatase enzyme is synthesized by the body. Its steroidal structure also gives it mild androgenic and anabolic properties.

Oral steroidal compound. No traditional ester. Once-daily dosing sufficient due to 24-hour half-life and the permanent enzyme inactivation mechanism. The permanent inactivation is an important practical consideration — if estrogen drops too low, it takes longer to recover than with non-steroidal AIs because new enzyme must be synthesized rather than just clearing the inhibitor.

Exemestane serves the same function as Anastrozole in performance settings — managing estrogen elevation from aromatizing androgens. Some users prefer it over non-steroidal AIs because of the mild anabolic properties from its steroidal structure and because it does not suppress IGF-1 the way non-steroidal AIs might. It is used throughout aromatizing cycles at doses sufficient to control estrogen-related symptoms without crashing estrogen entirely.

Exemestane is used in the same stacking contexts as Anastrozole — alongside aromatizing compounds to manage estrogen. It is added to testosterone-based protocols and to Boldenone cycles. It is not needed alongside non-aromatizing compounds like Trenbolone, Masteron, or Stanozolol. Some users prefer it over Anastrozole specifically when running protocols that include IGF-1-sensitive goals because non-steroidal AIs may suppress IGF-1 through a separate pathway.

• Breast cancer in postmenopausal women — approved first-line treatment
• Adjuvant therapy after breast cancer surgery
• Male gynecomastia
• Aromatase excess syndrome

• Estrogen crash — joint pain, low libido, depression, cardiovascular risk
• Bone density reduction with prolonged use
• Hot flashes
• Mood changes from estrogen deficiency
• Slower recovery than non-steroidal AIs if estrogen crashes
• Mild androgenic effects from steroidal structure

The permanent enzyme inactivation is a risk in both directions. If estrogen is well-controlled and you stop Exemestane, the suppression continues until new aromatase is synthesized — this can actually be an advantage for consistent control. But if estrogen crashes from too high a dose, recovery is slower than with non-steroidal AIs. The risks of estrogen deficiency — joint pain, cardiovascular risk, bone density loss, mood depression — apply equally to Exemestane as to any AI. The key difference is the time to recovery if you overshoot.

WADA bans aromatase inhibitors. Specific detection methodology available.